Stockholm - Delayed Quote SEK
IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
At close: October 18 at 4:59 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
41,585.00
5,678.00
61,136.00
207,782.00
--
--
Cost of Revenue
--
--
--
39,091.00
--
--
Gross Profit
--
--
61,136.00
168,691.00
--
--
Operating Expense
160,712.00
186,444.00
174,359.00
116,239.00
91,562.00
--
Operating Income
-119,127.00
-180,766.00
-113,223.00
52,452.00
-91,562.00
--
Net Non Operating Interest Income Expense
-329.00
2,927.00
-297.00
-369.00
-194.00
--
Pretax Income
-119,454.00
-177,839.00
-113,406.00
51,781.00
-91,653.00
--
Net Income Common Stockholders
-119,454.00
-177,839.00
-113,406.00
51,781.00
-91,653.00
--
Diluted NI Available to Com Stockholders
-119,454.00
-177,839.00
-113,406.00
51,781.00
-91,653.00
--
Basic EPS
-2.31
-3.43
-2.19
1.00
-1.92
--
Diluted EPS
-2.31
-3.43
-2.19
1.00
-1.92
--
Basic Average Shares
51,869.41
51,868.41
51,831.91
51,748.41
47,677.73
--
Diluted Average Shares
51,869.41
51,868.41
51,831.91
51,748.41
47,677.73
--
Total Operating Income as Reported
-119,124.00
-180,765.00
-113,110.00
52,576.00
-91,458.00
--
Total Expenses
160,712.00
186,444.00
174,359.00
155,330.00
91,562.00
--
Net Income from Continuing & Discontinued Operation
-119,454.00
-177,839.00
-113,406.00
51,781.00
-91,653.00
--
Normalized Income
-119,454.00
-177,839.00
-113,406.00
51,781.00
-91,653.00
--
Interest Income
4,354.00
3,125.00
--
1.00
1.00
--
Interest Expense
4,683.00
198.00
297.00
370.00
195.00
--
Net Interest Income
-329.00
2,927.00
-297.00
-369.00
-194.00
--
EBIT
-114,771.00
-177,641.00
-113,109.00
52,151.00
-91,458.00
--
EBITDA
-110,317.00
-173,325.00
-108,330.00
55,625.00
-89,202.00
--
Reconciled Cost of Revenue
--
--
--
39,091.00
--
--
Reconciled Depreciation
4,454.00
4,316.00
3,982.00
3,474.00
2,256.00
--
Net Income from Continuing Operation Net Minority Interest
-119,454.00
-177,839.00
-113,406.00
51,781.00
-91,653.00
--
Total Unusual Items Excluding Goodwill
--
--
--
--
--
74.00
Total Unusual Items
--
--
--
--
--
74.00
Normalized EBITDA
-110,317.00
-173,325.00
-108,330.00
55,625.00
-89,202.00
--
12/31/2019 - 2/28/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ZICC.ST Ziccum AB (publ)
2.3000
0.00%
VICO.ST Vicore Pharma Holding AB (publ)
8.62
-6.00%
SYNACT.ST SynAct Pharma AB
8.73
-0.06%
ACE.ST Ascelia Pharma AB (publ)
2.2050
+1.85%
FLUI.ST Fluicell AB (publ)
0.0736
+1.66%
DMYD-B.ST Diamyd Medical AB (publ)
13.50
+1.50%
ISOFOL.ST Isofol Medical AB (publ)
3.9500
-2.11%
TTNP Titan Pharmaceuticals, Inc.
4.7900
-0.10%
SNTI Senti Biosciences, Inc.
2.2800
+6.05%
MNPR Monopar Therapeutics Inc.
5.50
-3.68%